Aktienanalyse zu Invivyd Inc (IVVD)IVVDInvivyd Inc

Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Invivyd Inc is not a good buy right now due to its current price of $0.582, which is significantly below its 52-week high of $3.07, and a troubling RSI of 32.43 indicating oversold conditions. The company faces substantial risks, including a net income loss of $44,393,000 in Q2 2026 and a 76.72% year-to-date decline, suggesting a challenging financial environment. While analysts see potential upside, the current financial performance and market sentiment are concerning.